Urologists 'Outraged' Over PSA Test Challenge
The report said that over-diagnosis and overtreatment becomes an "inevitability" with PSA testing, which "means that many men will experience the adverse effects of diagnosis and treatment of a disease that would have remained asymptomatic throughout their lives. Assessing the balance of benefits and harms requires weighing a moderate to high probability of early and persistent harm from treatment against the very low probability of preventing a death from prostate cancer in the long term," the report said.
Siegel said the report ignores or fails to explain the dramatic decrease in deaths from prostate cancer over the last several decades.
"About 250,000 men are diagnosed with prostate cancer each year. That has stayed pretty stable. It is the death rates that have come down significantly," he says.
"In the last 30 years the deaths have dropped from 48,000 to 28,000 a year. The surgery is better. The radiation is somewhat better. But there haven't been significant advances except in some of the surgical techniques to explain this, other than screening."
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- 3 Traits Personality Assessments Can't Reveal
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Carondelet to Pay $35M to Settle Fraud Allegations
- CHS Hacked, 4.5M Patient Records Compromised